Final Term Sheet
Filed Pursuant to Rule 433
Registration Statement No. 333-258194
March 6, 2023
Marsh & McLennan Companies, Inc.
$600,000,000 5.450% Senior Notes due 2053
Issuer: | Marsh & McLennan Companies, Inc. | |
Securities: | 5.450% Senior Notes due 2053 | |
Offering Format: | SEC-Registered | |
Trade Date: | March 6, 2023 | |
Settlement Date*: | March 9, 2023 (T+3) | |
Expected Ratings / Outlook (Moody’s / S&P / Fitch)**: | Baa1 (Positive) / A- (Stable) / A- (Stable) | |
Maturity Date: | March 15, 2053 | |
Principal Amount: | $600,000,000 | |
Net Proceeds to Issuer (before offering expenses): | $591,318,000 | |
Use of Proceeds: | The net proceeds of this offering will be used for general corporate purposes. | |
Price to Public: | 99.428% of Principal Amount, plus accrued interest, if any, from March 9, 2023 | |
Benchmark Treasury: | 4.00% due November 15, 2052 | |
Benchmark Treasury Price and Yield: | 101-13; 3.919% | |
Spread to Benchmark Treasury: | + 157 basis points | |
Re-Offer Yield: | 5.489% | |
Coupon: | 5.450% | |
Interest Payment Dates: | Semi-annually on March 15 and September 15 of each year, commencing on September 15, 2023 | |
Optional Redemption – Make-Whole Call: | The greater of (1)(a) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes discounted to the redemption date (assuming the Notes matured on the Par Call date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 25 basis points less (b) interest accrued to the date of redemption, and (2) 100% of the principal amount of the Notes to be redeemed, plus, in either case, accrued and unpaid interest thereon to the redemption date. | |
Optional Redemption – Par Call: | On or after September 15, 2052, six months prior to the Maturity Date | |
CUSIP / ISIN: | 571748 BT8 / US571748BT86 |
Joint Book-Running Managers: | Barclays Capital Inc. HSBC Securities (USA) Inc. Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC Scotia Capital (USA) Inc. | |
Co-Managers: | BNP Paribas Securities Corp. RBC Capital Markets, LLC Standard Chartered Bank TD Securities (USA) LLC U.S. Bancorp Investments, Inc. |
* | Note: Under Rule 15c6-1 under the Securities Exchange Act, trades in the secondary market are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on any date prior to two business days before delivery will be required, by virtue of the fact that the notes initially settle in T+3, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes during such period should consult their advisors. |
** | Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision, suspension or withdrawal at any time. Each credit rating should be evaluated independently of any other credit rating. |
The issuer has filed a registration statement, including a prospectus and a related preliminary prospectus supplement, with the SEC for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus supplement, the prospectus in the registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Joint Book-Running Managers will arrange to send you the prospectus and prospectus supplement if you request it by contacting: (i) Barclays Capital Inc. toll-free at 1-888-603-5847, (ii) HSBC Securities (USA) Inc. at 1-866-811-8049 or (iii) Morgan Stanley & Co. LLC toll-free at 1-866-718-1649.
This communication should be read in conjunction with the preliminary prospectus supplement and the accompanying prospectus. The information in this communication supersedes the information in the preliminary prospectus supplement and the accompanying prospectus to the extent it is inconsistent with the information in such preliminary prospectus supplement or the accompanying prospectus.
Any disclaimers or other notices that may appear below are not applicable to this communication and should be disregarded. Such disclaimers or other notices were automatically generated as a result of this communication being sent via Bloomberg or another email system.
- 2 -